[{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"6a7e9990-a739-46e3-a955-92f98bf580c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04927416","created_at":"2021-06-16T18:52:38.190Z","updated_at":"2025-02-25T15:35:06.877Z","phase":"Phase 2","brief_title":"The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer","source_id_and_acronym":"NCT04927416","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 overexpression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 11/30/2030","primary_completion_date":" 11/30/2030","study_txt":" Completion: 11/30/2030","study_completion_date":" 11/30/2030","last_update_posted":"2025-02-10"},{"id":"34339220-1770-4108-8649-484d7d43cefa","acronym":"212-Pb-VMT","url":"https://clinicaltrials.gov/study/NCT05636618","created_at":"2022-12-05T15:56:36.062Z","updated_at":"2025-02-25T17:38:15.153Z","phase":"Phase 1/2","brief_title":"Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors","source_id_and_acronym":"NCT05636618 - 212-Pb-VMT","lead_sponsor":"Perspective Therapeutics","biomarkers":" SSTR • CD4 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR • CD4 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-𝛼-NET"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/27/2023","start_date":" 09/27/2023","primary_txt":" Primary completion: 11/26/2029","primary_completion_date":" 11/26/2029","study_txt":" Completion: 12/26/2029","study_completion_date":" 12/26/2029","last_update_posted":"2025-01-29"},{"id":"8e9016c5-f335-427f-9f26-0ca96ab2e497","acronym":"LANTana","url":"https://clinicaltrials.gov/study/NCT05178693","created_at":"2022-01-05T12:53:41.791Z","updated_at":"2025-02-25T15:54:18.184Z","phase":"Phase 1","brief_title":"Lutathera and ASTX727 in Neuroendocrine Tumours","source_id_and_acronym":"NCT05178693 - LANTana","lead_sponsor":"Imperial College London","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"a595dd39-de19-445b-833b-30837dcc200d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610826","created_at":"2022-11-09T13:56:42.488Z","updated_at":"2024-07-02T16:35:21.904Z","phase":"Phase 1/2","brief_title":"Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver","source_id_and_acronym":"NCT05610826","lead_sponsor":"University of Chicago","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-01-29"},{"id":"0d0d15de-eb4a-4e35-9e1e-388c588b5f9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971461","created_at":"2021-01-18T19:32:12.909Z","updated_at":"2024-07-02T16:35:40.851Z","phase":"Phase 2","brief_title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","source_id_and_acronym":"NCT03971461","lead_sponsor":"NYU Langone Health","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-08-04"},{"id":"466aa3f3-e407-4613-8085-e7a9cfdf7bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01967537","created_at":"2021-02-11T16:52:52.795Z","updated_at":"2024-07-02T16:36:53.453Z","phase":"Phase 2","brief_title":"Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors","source_id_and_acronym":"NCT01967537","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression • SSTR2 overexpression","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression • SSTR2 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 341","initiation":"Initiation: 10/18/2013","start_date":" 10/18/2013","primary_txt":" Primary completion: 12/17/2017","primary_completion_date":" 12/17/2017","study_txt":" Completion: 03/12/2018","study_completion_date":" 03/12/2018","last_update_posted":"2019-11-19"},{"id":"fbc4a57d-196c-41c2-ba51-81874dc4d553","acronym":"","url":"https://clinicaltrials.gov/study/NCT02030184","created_at":"2021-03-16T19:52:12.023Z","updated_at":"2024-07-02T16:36:54.486Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas","source_id_and_acronym":"NCT02030184","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan • Tozaride (Rhenium (Re) 188 P2045)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2019-10-17"},{"id":"5bc3659a-3c01-4ab0-9123-c52ef8ae03e1","acronym":"PRRT","url":"https://clinicaltrials.gov/study/NCT02441088","created_at":"2021-02-11T16:53:07.376Z","updated_at":"2024-07-02T16:37:00.103Z","phase":"Phase 2","brief_title":"Theranostics: 68GaDOTATOC and 90YDOTATOC","source_id_and_acronym":"NCT02441088 - PRRT","lead_sponsor":"Sue O'Dorisio","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"],"overall_status":"Unknown status","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-04-29"},{"id":"f58b8b00-fae4-43ae-b2d5-28f40ae2d43b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03013387","created_at":"2021-02-11T16:53:18.770Z","updated_at":"2024-07-02T16:37:18.458Z","phase":"Phase 2","brief_title":"Dosimetry Guided PRRT With 90Y-DOTATOC","source_id_and_acronym":"NCT03013387","lead_sponsor":"Sue O'Dorisio","biomarkers":" SSTR • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2017-08-25"}]